SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

Dexcom Inc. DXCM, a leading glucose monitor manufacturer, has enabled direct Apple Inc.’s AAPL Watch connectivity for its G7 model in the United States. What Happened: The new feature allows G7 users ...

Dexcom G7 continuous glucose monitor users can now monitor their blood sugar data in real time on an Apple Watch without having their iPhone to hand, the U.S. medical device manufacturer has announced ...

The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

People with diabetes can use continuous glucose monitors (CGMs) to make tracking their blood sugar levels easier. Instead of drawing blood multiple times per day, a person continuously wears a sensor ...

Once paired, you’ll be able to leave your iPhone behind while still getting real-time readings. Once paired, you’ll be able to leave your iPhone behind while still getting real-time readings. is a ...

In addition to improved accuracy, the Dexcom G7 15 Day allows for 15.5 days of wear. The Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM) system ...

Users can go to dexcom.com/theft-check for information on how to determine if sensors are from the affected lots and what ...

Add Yahoo as a preferred source to see more of our stories on Google. (COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in ...

DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...